Raising Awareness for Hereditary Angioedema: A European Initiative on World HAE Day#Milan#Ireland#Hereditary_Angioedema#BioCryst_Ireland#World_HAE_Day
Raising Awareness for Hereditary Angioedema: A European Initiative on World HAE Day
On World HAE Day, BioCryst Ireland highlights hereditary angioedema through expert discussions and educational initiatives, aiming for better patient outcomes.
third-news.com
May 13, 2026 at 7:16 PM
Raising Awareness for Hereditary Angioedema: A European Initiative on World HAE Day#Milan#Ireland#Hereditary_Angioedema#BioCryst_Ireland#World_HAE_Day
CSL Behring Launches Campaign to Raise Awareness for HAE on HAE Day 2023#Japan#Tokyo#CSL_Behring#Hereditary_Angioedema#HAE_Day
CSL Behring Launches Campaign to Raise Awareness for HAE on HAE Day 2023
In honor of HAE Day 2023, CSL Behring conducted various initiatives to enhance awareness and understanding of Hereditary Angioedema, a rare disease.
third-news.com
May 15, 2026 at 6:22 AM
CSL Behring Launches Campaign to Raise Awareness for HAE on HAE Day 2023#Japan#Tokyo#CSL_Behring#Hereditary_Angioedema#HAE_Day
KLKB1 Inhibitors Market Poised for Remarkable Growth by 2034 Thanks to Innovative Therapies#None#targeted_therapies#Hereditary_Angioedema#KLKB1_Inhibitors
KLKB1 Inhibitors Market Poised for Remarkable Growth by 2034 Thanks to Innovative Therapies
The KLKB1 inhibitors market is set for substantial growth by 2034, propelled by new therapies and a focus on personalized medicine in treating rare diseases.
third-news.com
November 19, 2025 at 10:41 PM
KLKB1 Inhibitors Market Poised for Remarkable Growth by 2034 Thanks to Innovative Therapies#None#targeted_therapies#Hereditary_Angioedema#KLKB1_Inhibitors
CSL Behring Publishes Archive of HAE Online Public Lecture on Patient Challenges#Japan#Tokyo#HAE#CSL_Behring#Hereditary_Angioedema
CSL Behring Publishes Archive of HAE Online Public Lecture on Patient Challenges
CSL Behring has released an archive of an online public lecture on hereditary angioedema, focusing on patient experiences and challenges. This initiative aims to improve quality of life for HAE patients.
third-news.com
September 11, 2025 at 2:52 AM
CSL Behring Publishes Archive of HAE Online Public Lecture on Patient Challenges#Japan#Tokyo#HAE#CSL_Behring#Hereditary_Angioedema
European Medicines Agency Approves New Delivery Option for TAKHZYRO® to Aid HAE Patients Over 12#None#Takeda#TAKHZYRO#Hereditary_Angioedema
European Medicines Agency Approves New Delivery Option for TAKHZYRO® to Aid HAE Patients Over 12
The EMA has approved a new 2 mL pre-filled pen for TAKHZYRO®, enhancing treatment convenience for patients aged 12 and above with hereditary angioedema.
third-news.com
February 24, 2025 at 8:08 AM
European Medicines Agency Approves New Delivery Option for TAKHZYRO® to Aid HAE Patients Over 12#None#Takeda#TAKHZYRO#Hereditary_Angioedema